138 related articles for article (PubMed ID: 33714260)
1. The impact of Ki-67 index, squamous differentiation, and several clinicopathologic parameters on the recurrence of low and intermediate-risk endometrial cancer.
Ocak B; Atalay FÖ; Sahin AB; Ozsen M; Dakiki B; Türe S; Mesohorli M; Odman HU; Tanrıverdi Ö; Ocakoğlu G; Bayrak M; Ozan H; Demiröz C; Sali S; Orhan SO; Deligönül A; Cubukcu E; Evrensel T
Bosn J Basic Med Sci; 2021 Feb; 21(5):549-554. PubMed ID: 33714260
[TBL] [Abstract][Full Text] [Related]
2. Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
Andrade DAP; da Silva VD; Matsushita GM; de Lima MA; Vieira MA; Andrade CEMC; Schmidt RL; Reis RM; Dos Reis R
PLoS One; 2019; 14(10):e0220086. PubMed ID: 31600211
[TBL] [Abstract][Full Text] [Related]
3. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for tumor recurrence in endometrioid endometrial cancer stages IA and IB.
Han KH; Kim HS; Lee M; Chung HH; Song YS
Medicine (Baltimore); 2017 May; 96(21):e6976. PubMed ID: 28538399
[TBL] [Abstract][Full Text] [Related]
5. Why do some patients with stage 1A and 1B endometrial endometrioid carcinoma experience recurrence? A retrospective study in search of prognostic factors.
Ocak B; Sahin AB; Oz Atalay F; Ozsen M; Dakiki B; Ture S; Sali S; Tanriverdi O; Bayrak M; Ozan H; Demiroz Abakay C; Deligonul A; Cubukcu E; Evrensel T
Ginekol Pol; 2021 Jun; ():. PubMed ID: 34105738
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
7. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.
Worley MJ; Davis M; Berhie SH; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS; Campos SM
Gynecol Oncol; 2014 Oct; 135(1):54-7. PubMed ID: 25088333
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
10. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
13. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
14. Possible Risk Factors of Pulmonary Metastases in Patients With International Federation of Gynecology and Obstetrics Stage I Endometrioid-Type Endometrial Cancer.
Jiang W; Chen J; Tao X; Huang F; Zhu M; Wang C; Feng W
Int J Gynecol Cancer; 2017 Jul; 27(6):1206-1215. PubMed ID: 28448305
[TBL] [Abstract][Full Text] [Related]
15. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
16. Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.
Akbayır O; Corbacıoglu Esmer A; Numanoglu C; Cılesız Goksedef BP; Akca A; Bakır LV; Kuru O
Arch Gynecol Obstet; 2012 Nov; 286(5):1269-76. PubMed ID: 22729137
[TBL] [Abstract][Full Text] [Related]
17. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study.
Salvesen HB; Iversen OE; Akslen LA
J Clin Oncol; 1999 May; 17(5):1382-90. PubMed ID: 10334522
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study.
Chao X; Wu M; Ma S; Tan X; Zhong S; Bi Y; Wu H; Lang J; Li L
Sci Rep; 2020 Apr; 10(1):5984. PubMed ID: 32249826
[TBL] [Abstract][Full Text] [Related]
20. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
